PracticeMatch

PracticeMatch connects physicians and advanced practitioners with potential employers through a unique set of sourcing tools, allowing both to find their perfect match. Company Overview PracticeMatch is the premier source for physician data and recruitment services for in-house physician recruiters. We are backed by the strength of our graduating and practicing physician databases-- the two most highly-regarded databases in the industry.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

AXIM BIOTECH DEVELOPS RAPID QUANTITATIVE TEAR TEST FOR MMP-9, AN INFLAMMATORY BIOMARKER OF DRY EYE DISEASE

AXIM Biotech | March 10, 2022

news image

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for Dry Eye Disease. Dry Eye Disease, though widespread, is under-diagnosed, in part because symptoms do not always correlate with objective signs. It has a highly vari...

Read More

CELL AND GENE THERAPY

MATICA BIO ANNOUNCES JOINT RESEARCH AGREEMENT WITH SARTORIUS FOR THE DEVELOPMENT OF ADVANCED VIRAL VECTOR MANUFACTURING TECHNOLOGY

Matica Biotechnology, Inc. | October 19, 2021

news image

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offe...

Read More

CELL AND GENE THERAPY

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

news image

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More

MEDICAL

GENELUX AND NEWSOARA ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR ONCOLYTIC IMMUNOTHERAPIES

Genelux Corporation | September 29, 2021

news image

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Read More
news image

MEDICAL

AXIM BIOTECH DEVELOPS RAPID QUANTITATIVE TEAR TEST FOR MMP-9, AN INFLAMMATORY BIOMARKER OF DRY EYE DISEASE

AXIM Biotech | March 10, 2022

AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for Dry Eye Disease. Dry Eye Disease, though widespread, is under-diagnosed, in part because symptoms do not always correlate with objective signs. It has a highly vari...

Read More
news image

CELL AND GENE THERAPY

MATICA BIO ANNOUNCES JOINT RESEARCH AGREEMENT WITH SARTORIUS FOR THE DEVELOPMENT OF ADVANCED VIRAL VECTOR MANUFACTURING TECHNOLOGY

Matica Biotechnology, Inc. | October 19, 2021

Matica Biotechnology, Inc, (Matica Bio) a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on a number of studies together to streamline and optimize PAT technologies, automation software, and single-use platforms offe...

Read More
news image

CELL AND GENE THERAPY

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More
news image

MEDICAL

GENELUX AND NEWSOARA ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR ONCOLYTIC IMMUNOTHERAPIES

Genelux Corporation | September 29, 2021

Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have exclusive rights in Greater China (mainland China, Hong Kong, Macau and Taiwan) to Olvi-Vec for which Genelux currently is planning a U.S. based Phase 3 registration trial in platinum resistant/refr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us